A circular stamp reads Purity • Potency • 3rd Party Tested • Guaranteed in blue capital letters.

BATCH

PURITY

99% HPLC

GLP-3: RT

Appetite ReshapingVisceral Fat ReductionWeight Loss

Price range: $140.00 through $425.00

Volume Pricing Guide

QUANTITY PRICE PER
1 $140.00
2 - 4 $126.00
5 - 9 $119.00
10 - 14 $112.00
15 - 19 $105.00
20 + $98.00

Only the lyophilized product is provided. For research use only. All supplies sold separately.  

Section divider line

Summary

Retatrutide (LY3437943) is a groundbreaking investigational peptide therapy that activates three key metabolic hormone receptors—GLP-1, GIP, and glucagon—delivering unprecedented weight loss outcomes. In phase 2 trials, participants achieved up to a 24.2% reduction in body weight over 48 weeks, surpassing results from existing GLP-1 or dual agonist therapies . This triple-agonist approach not only enhances satiety and insulin sensitivity but also increases energy expenditure, offering a comprehensive strategy for metabolic health restoration.

Research Recommendations

Section divider line

Batch Testing Reports

Section divider line

Description & Pharmacodynamics

GLP-3 (RT)’s unique mechanism of action involves simultaneous activation of:

  • GLP-1 Receptors: Enhances insulin secretion, delays gastric emptying, and promotes satiety.
  • GIP Receptors: Improves insulin sensitivity and supports lipid metabolism.
  • Glucagon Receptors: Increases energy expenditure and promotes fat oxidation.

This synergistic activation leads to:

  • Significant Weight Reduction: Up to 24.2% body weight loss observed in clinical trials .
  • Improved Glycemic Control: Enhanced insulin sensitivity and glucose regulation.

Cardiometabolic Benefits: Potential improvements in blood pressure and lipid profiles.

Section divider line

Research Insights

Superior Weight Loss Outcomes
In a 48-week phase 2 study, adults with obesity treated with retatrutide experienced mean weight reductions of 22.8% (8 mg dose) and 24.2% (12 mg dose), outperforming other weight loss medications .

Enhanced Metabolic Health
Beyond weight loss, retatrutide has demonstrated potential in reducing liver fat content, indicating benefits for conditions like metabolic dysfunction-associated steatotic liver disease (MASLD) .

Tolerability and Safety
Common side effects were primarily gastrointestinal and occurred mainly during dose escalation phases. These effects were generally mild to moderate and transient .

Section divider line

Structure

GLP-3 (RT) Sequence:
YA¹QGTFTSDYSIL²LDKK⁴AQA¹AFIEYLLEGGPSSGAPPPS³
Note: Superscript numbers indicate specific chemical modifications enhancing stability and receptor activity.

Molecular Formula: Variable
Molecular Weight: Variable
PubChem CID: Not yet assigned

Section divider line

Citations for GLP-3: RT

  1.  GLP-3 (RT) is an innovative therapeutic agent designed to address metabolic conditions.  As research continues, GLP-3 (RT) shows promise in reshaping the landscape of metabolic disease management. Jastreboff, A. M., et al. (2023). Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity. The New England Journal of Medicine
  2. Nature Medicine. (2024). Triple hormone receptor agonist GLP-3 (RT) for metabolic dysfunction. 
  3. American Diabetes Association. (2023). Highlights Novel Agent GLP-3 (RT) Results: Substantial Weight Reduction.

**Note:** This product is intended for research purposes only and not for human consumption. Always consult with a healthcare professional before starting any new supplement or research product.

Researched Pairings